Familial adenomatous polyposis (FAP) is an autosomal dominant condition characterized by the development of hundreds to thousands of colorectal adenomatous polyps. In addition to the classic form, there is also attenuated polyposis (attenuated adenomatous polyposis coli; AAPC), which is characterized by a milder phenotype. FAP/AAPC is caused by germline mutations in the adenomatous polyposis coli (APC) gene. Very recently, germline mutations in the base-excision repair gene MYH have been associated with recessive inheritance of multiple colorectal adenomas in a subset of patients. APC pathogenic alterations are mostly (Ͼ95%) represented by frameshift or nonsense mutations leading to the synthesis of a truncated protein.
F
amilial adenomatous polyposis (FAP) (OMIM 175100) is an autosomal dominant condition characterized by the development of hundreds to thousands of colorectal adenomatous polyps, conferring a very high risk of cancer at a young age. In addition to the classic form, there is also attenuated polyposis (attenuated adenomatous polyposis coli; AAPC), which is characterized by the development of fewer than 100 adenomas and delayed age of cancer onset . Colorectal adenomas are the hallmark of FAP syndrome. However, in addition to polyps, affected individuals may also develop different clinical features, such as retinal lesions, desmoid tumors, and mandibular osteomas. Overall, patients with FAP show considerable phenotypic heterogeneity as exemplified by different number of adenomas, age of cancer onset, and extracolonic manifestations (reviewed in Vasen, 2000) .
FAP is caused by germline mutations in the adenomatous polyposis coli (APC) tumor suppressor gene, localized on chromosome 5q21-22 (Groden et al, 1991; Kinzler et al, 1991) . Pathogenic alterations are mostly (Ͼ95%) represented by frameshift or nonsense mutations leading to the synthesis of a truncated protein (Laurent-Puig et al, 1998; Powell et al, 1993) . Germline alterations are usually detected in 70% of classic patients with FAP and in 10% of patients with AAPC (Heinimann et al, 2001; Lamlum et al, 2000; Spirio et al, 1993; van der Luijt et al, 1996b) . A genotype-phenotype correlation has been observed by several authors, suggesting that clinical variability partially depends on the position of mutations along the gene (reviewed in Fodde and Khan, 1995; Pilarski et al, 1999; Spirio et al, 1993; Varesco et al, 1994; van der Luijt et al, 1995) .
Increasing evidence indicates that routinely used PCR-based molecular methods fail to detect APC mutations in 5% to 10% of patients and are inadequate for finding gene alterations such as large dele-tions or transcription defects (Laken et al, 1999; Mandl et al, 1996) . There are a minority of patients who do not show detectable APC mutations even after intensive gene screening (Laken et al, 1999) , suggesting the existence of additional susceptibility genes. Very recently, germline mutations in the base-excision-repair gene MYH have been associated with recessive inheritance of multiple colorectal adenomas in a subset of patients (Al-Tassan et al, 2002; Jones et al, 2002; Sieber et al, 2003) .
APC has a gatekeeper role in colonic homeostasis. The protein plays a role in the Wnt signaling pathway by catalyzing the degradation of ␤-catenin (Munemitsu et al, 1995; Rubinfeld et al, 1996) . As a consequence of APC inactivation, ␤-catenin accumulates in the cytoplasm and moves to the nucleus, where it mediates the transcription of Wnt target genes Tetsu and McCormick, 1999) . ␤-catenin also plays a role in cell-cell adhesion by interacting with E-cadherin at the adherens junctions (Orsulic et al, 1999) . Down-regulation of E-cadherin can be expected to shift ␤-catenin from adherens junctions to the cytoplasmic pool. However, no E-cadherin mutations have been demonstrated to directly increase ␤-catenin-dependent transcription of Wnt target genes (Suriano et al, 2003; van de Wetering et al, 2001; Wong and Gumbiner, 2003) . On the other hand, reduction of E-cadherin level has been shown to result in alterations of epithelial cell proliferation, migration, and apoptosis (Perry et al, 1999; Smits et al, 2000) .
In this study we thoroughly investigated FAP/AAPC patients who tested negative for APC truncating mutations. We used different approaches to search for APC alterations other than chain-terminating mutations and to assess whether either ␤-catenin (CT-NNB1) or E-cadherin (CDH1) gene mutations can substitute (or act in association with) APC alterations.
Results
Thirty individuals from different families proven to be affected by classic FAP (22 cases) or by AAPC (8 cases) were screened for APC-truncating mutations by protein truncation test (PTT). We identified 20 mutation carriers: 18 with classic polyposis (18/22: 80%) and 2 with AAPC (2/8: 25%) (p Ͻ 0.01 by Fisher's exact test). Phenotype heterogeneity was observed among mutation carriers (data not shown) as well as among patients without truncating mutations (clinical and pathologic features are reported in Table  1 ).
The 10 patients without apparent mutation, including 6 cases of AAPC and 4 of classic FAP, were further investigated for germline mutations in ␤-catenin (CT-NNB1) and E-cadherin (CDH1) genes, as well as for APC gene alterations other than protein-truncating mutations. Regarding CTNNB1, we first sequenced the 5' end (500 bp) of cDNA, where the majority of mutations occurring in sporadic colorectal cancer have been found (Samowitz et al, 1999) . The remaining part of cDNA was divided into four fragments that were analyzed by the enzymatic mutation detection (EMD) assay. The CDH1 gene was investigated by directly sequencing all exons, intron-exon boundaries, and the proximal promoter region. No CTNNB1 or CDH1 gene mutations were found.
To further investigate APC, we sequenced 500 bp at the 5' end of the cDNA. This was done to ensure that truncating mutations at the very 5' end of the coding region were not missed because of the running conditions we had used for PTT. We also searched for missense mutations along the entire coding region by means of the EMD assay. Neither missense nor truncating mutations at the very 5' end of the gene were found. To assess APC transcription level in mutationnegative patients, we performed a real-time quantitative RT-PCR analysis. The 10 samples showed a relative quantity of APC cDNA ranging from 0.52 to 1.4. Samples expressing one only allele were expected to give values close to 0.5. Accordingly, we considered patients who showed values from 0.52 to 0.64 (ie, Patients 1 to 4 in Table 2 ) as possible carriers of a nonfunctional allele.
To investigate whether a relatively lower mRNA level was compatible with a constitutive APC gene deletion, LGD, low-grade dysplasia; HGD, high-grade dysplasia; ND, not determined. a The father of this 16-year-old patient showed Ͻ70 colon polyps at 45 years of age.
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patients were genotyped for polymorphic markers mapping at the APC locus. We analyzed five intragenic single nucleotide polymorphisms (SNPs), from the promoter to the 3'-untranslated region (UTR), as well as two polymorphic microsatellites at the 3' of the gene. All subjects retained heterozygosity at one or more intragenic markers, with the exception of four patients (Patients 1, 2, 3, and 6 in Table 2 ) who proved to be homozygous (suggesting hemizygosity) for all intragenic markers. Taking into account both quantitative RT-PCR and genotyping results, our findings suggest a constitutive APC allelic deletion causing haploinsufficiency in three patients (Patients 1, 2, and 3 in Table 2 ). For one FAP patient (Patient 1 in Table 2 ), we could confirm this hypothesis by family investigation: the proband and two affected nieces were apparently homozygous for all tested markers and were carriers of three different haplotypes (Fig. 1) . Haplotype results can be explained by assuming hemizygosity at markers spanning the APC locus, consistent with a whole gene deletion cosegregating with FAP disease in the family. In other words, the three affected subjects do not share any haplotype, being carriers of the same allelic deletion encompassing the investigated markers.
Discussion
In this study we thoroughly investigated FAP/AAPC patients who tested negative for APC-truncating mutations by searching for APC alterations other than protein truncations and by analyzing both CTNNB1 and CDH1 genes. Because of their function and the relatively high mutation frequency in sporadic gastrointestinal tumors (Becker et al, 1994; Samowitz et al, 1999) , the CTNNB1 and CDH1 genes can be regarded as possible candidates in predisposition to colorectal cancer. Most of the previous studies on CTNNB1 in FAP patients have been performed by analyzing only exon 3 (Cao et al, 1999; Muller et al, 1998) , where the majority of somatic mutations have been found to occur in colorectal cancer (Samowitz et al, 1999) . However, it is conceivable that these mutations, deeply impairing ␤-catenin function, are not tolerated at the constitutive level. We extended the analysis to the entire CTNNB1 gene, including sites coding for competitive binding of APC, E-cadherin, and TCF4/ LEF-1 to ␤-catenin. However, similarly to other authors (Dobbie and Muller, 1999 ), we could not find any mutation. The same result was obtained for the CDH1 gene. To the best of our knowledge, this is the first analysis of the gene in FAP/AAPC kindreds. Up to now, the strongest evidence to support a causal role for E-cadherin alterations in cancer predisposition is still the finding that CDH1 mutations are linked to the hereditary diffuse gastric cancer syndrome (Guilford et al, 1998) . Moreover, Smits et al (2000) have demonstrated that constitutive Apc and E-cadherin gene mutations are synergistic in intestinal tumor initiation in mice, indicating that E-cadherin mutations enhance APC-driven tumors without affecting tumor progression. In FAP/AAPC patients with no detectable APCtruncating mutations, we also analyzed APC by both EMD and real-time quantitative RT-PCR methods. We observed deficiencies in gene expression in 4 of 10 subjects. Our results on polymorphic markers encompassing the APC locus were compatible with a constitutive allelic deletion in three of the four subjects. Whole gene deletion was supported by pedigree and haplotype analysis in one of these patients, although not proven at the molecular level.
We also found one patient with low APC gene expression who retains heterozygosity at the intragenic markers. This patient is likely to be carrier of a mutation within the APC locus. However, the precise nature of this APC defect may be difficult to define because Yan et al (2002) reported that in one FAP patient with a reduced expression of APC, the entire coding region, as well as the 3'-UTR and promoter, were completely normal. Sieber et al (2002) have recently developed an assay on genomic DNA to detect APC deletions. With this approach, 7 (12%) of 60 classic FAP and 0 of 143 AAPC patients without apparent APC mutations proved to carry a full gene deletion. These patients were from different European origin. No deletions were detected in 18 APC mutation-negative FAP kindreds from Finland (Moisio et al, 2002) . On the contrary, De Rosa et al (1999) reported gene deletions in three (33%) of nine mutation-negative FAP families of Italian origin. Our study on Italian patients suggested gene deletion in 3 of 10 cases. Further studies are needed to more precisely evaluate APC deletion frequency in relation to the origin of patients. Our panel of mutation negative cases also includes six subjects with normal (or slightly reduced) APC gene expression. Despite the mutation strategy we used, we could have missed gene alterations in these cases (20% of all tested cases). Moisio et al (2002) , by using a comprehensive mutation detection strategy, could not identify APC alterations in 28% of Finnish FAP kindreds, including deletions and imbalance in allelic expression.
In the light of the most recent findings (Al-Tassan et al, 2002; Jones et al, 2002; Sieber et al, 2003) , mutation assessment of the MYH base-excisionrepair gene in APC alteration-negative patients might represent a relevant issue.
In conclusion, we have shown that constitutive APC-reduced expression is present in a fraction of polyposis patients (4/10) with no detectable truncating mutations within the APC coding region. However, 6 of 30 patients with a clinical diagnosis of polyposis did not show evidence of APC mutation after intensive molecular screening. We can exclude that mutations of the CTNNB1 and CDH1 genes play a significant role in FAP/AAPC predisposition.
Materials and Methods

Patients
Blood samples were obtained from 30 unrelated patients of Italian origin who were diagnosed with FAP or AAPC on the basis of family history and/or endoscopic assessment of colonic polyps. Adenomas were diagnosed and typed according to the World Health Organization criteria (Jass et al, 1990) . Overall, 22 patients displayed more than 100 colorectal adenomas (classic FAP) and 8 patients displayed less than 100 adenomas (AAPC). The mean age at polyposis diagnosis was 31 (range, 16 -42) years for classic FAP and 40 (range, 16 -65) years for AAPC. All patients showed polyps throughout the entire colon; only one patient had extracolonic manifestations (osteomas). After informed consent, blood samples were obtained from one affected individual per family (from three affected subjects in one case) and used for DNA and RNA extraction. DNA and RNA were extracted from lymphocytes by using standard procedure and the QIamp RNA Blood Mini Kit (Qiagen), respectively. 
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APC gene analysis
PTT. Truncating mutations were investigated by PTT. PTT was performed using a set of primers that allow amplification of the entire cDNA (http://www.ncbi.nih.gov/genebank/; Accession Number M73548) into five overlapping fragments (Bala et al, 1996; van der Luijt et al, 1996a) . Fragments 2 to 5 encompassing exon 15 were obtained by directly amplifying genomic DNA by means of Taq Extender (Stratagene). Fragment 1, encompassing exons 1 to 14, was obtained by RT-PCR using hexamer primers according to the First Strand Synthesis Kit procedure (Roche). PCR products were used for PTT. The PTT was performed using a TnT/T7 coupled reticulocyte lysate system (Promega). Translation products were loaded on a 14% Tris-glycine-SDS polyacrylamide gel (Bio-Rad). Samples showing a bandshift were reamplified by PCR and sequenced on an ALFexpress II Sequencer (Amersham Biosciences) by using the AutoLoad Solid Phase Sequencing kit (Amersham Biosciences). Results were analyzed by the ALFwin 2.00 program (Amersham Biosciences).
EMD. Base changes were investigated by the Passport Mutation Scanning Kit (Amersham Biosciences), an EMD system. This method, based on the recognition and cleavage of mismatches in duplex DNA molecules by T4 Endonuclease VII, allows mutation detection with approximately 100% sensitivity and 94% specificity compared with the DNA direct sequencing method (Del Tito et al, 1998) . Thirteen overlapping fragments (600 -1200 bp) covering the entire APC coding region were amplified by PCR using Cy5 fluorescent-labeled primers (Table 3) . Following the manufacturer's instructions, each fragment was hybridized with the corresponding wild-type sequence DNA and subjected to enzymatic cleavage by T4 Endonuclease VII. Cleavage fragments were analyzed on an ALFexpress II Sequencer by the ALFwin Fragment Analyser 1.0 Program (Amersham Biosciences).
Genotype Analysis. Genotypes were determined at seven different polymorphic markers encompassing the APC locus. The following five markers were SNPs intragenic to APC: rs 2019720, located in the promoter region; APC 1458, located within exon 11; APC 5037, located within exon 15K; FB54D, located within exon 15N; and 37A/37B, located within the 3'-UTR. Patients were also genotyped for two microsatellite markers, D5S346 and D5S656, located at 32 kb and 628 kb 3'of APC, respectively. All selected SNPs were characterized by allele frequencies close to 0.50. We amplified the polymorphic regions by using primers and PCR conditions as reported at the Genome Database (Gibson et al, 1996; Holland et al, 1991) . In addition to the standard PCR components, this assay requires an oligonucleotide probe specific to a sequence between two primers. The probe is labeled with two different fluorophores, a reporter dye at the 5' end and a quencher dye at the 3' end. Fluorescence emission from the reporter is absorbed by the quencher. During the extension phase of each PCR cycle, TaqDNA polymerase cleaves the probe annealed between the two primers. The cleavage, by separating the two dyes, enables detection of the reporter fluorescence. The resulting increase in reporter emission is directly proportional to the amount of product generated by each PCR cycle. We obtained APC cDNA by RT-PCR as described above. A cDNA fragment of 88 bp, covering the exon 2 to 3 juxtaposition, was used as a target for the assay (Table 3) . A cDNA fragment from the GAPDH gene was used as an internal control (Applied Biosystems). APC and GAPDH probes were labeled at the 5' ends with the reporter dyes FAM and JOE, respectively, and at the 3' ends with the TAMRA quencher dye (Applied Biosystem). Both the APC primers and probe were designed by using PRIMER EXPRESS software (Applied Biosystems). Probe and primer sequences are listed in Table  3 . Real-time quantitative RT-PCR was performed in 25 l containing 1ϫ Taq Man Universal Master mix (Applied Biosystems). The optimal APC amplification conditions were as follows: 200 nM for the probe in the presence of 900 nM forward and 150 nM reverse primers. The optimal GAPDH amplification conditions were those suggested by the manufacturer (Applied Biosystems). Amplification reactions were performed for 2 minutes at 50°C and 10 minutes at 95°C, followed by 40 cycles of denaturation at 95°C for 15 seconds and annealing at 60 C°for 1 minute. We performed two independent experiments. Each experiment comprised (in triplicate) control samples from 2 healthy individuals, samples from the 10 patients with undetectable APC mutations, and 2 no-template controls. The reporter emission was measured by an ABI PRISM 7700 Sequence Detection System (Applied Biosystems): the signal is normalized to an internal reference and the software sets the threshold cycle (C T ) when the reference becomes equal to 10 standard deviations of the baseline. We quantified the target APC cDNA by calculating the 2 Ϫ(⌬⌬C T ) value where ⌬⌬C T ϭ ⌬C T1 (C T APC Ϫ C T GAPDH) Ϫ ⌬C T2 (C T Calibrator Ϫ C T GAPDH). We used as a calibrator the sample with the lower C T value. We normalized the 2 Ϫ(⌬⌬C T ) mean value of each patient sample against the 2 Ϫ(⌬⌬C T ) mean value of the healthy control subjects. By this approach, samples normally expressing both alleles are expected to give values close to 1, whereas samples expressing only one allele are expected to give values close to 0.5. Table 2 shows mean values from the two independent experiments.
␤-Catenin Gene (CTNNB1) Mutation Analysis
The entire ␤-catenin cDNA was amplified into five fragments of 600 bp each. Primers are reported in Table 3 . The PCR fragment corresponding to the 5' terminal region, including the complete GSK3␤ phosphorylation consensus motif, was analyzed by direct sequencing as described above. The other four PCR products, encompassing the 12 Armadillo repeats, were subjected to EMD as above.
E-Cadherin Gene (CDH1) Mutation Analysis
The 16 exons and part of the promoter region of the gene were amplified by PCR using the primers and reaction conditions reported by Berx et al (1995) . PCR products were sequenced. Sequencing reactions were performed in forward and reverse by using the Big Dye Terminator Cycle Sequencing Ready Reaction Kit (PE) and analyzed on an ABI Prism 310 sequencer (PE).
